Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) – Drugs In Development, 2024 report and make more profitable business decisions.
Pneumocystis pneumonia (PCP) is an infectious lung disease caused by Pneumocystis jirovecii fungi. A compromised immune system is the main risk factor for PCP. Sudden fever, cough, trouble breathing, chest tightness, and weight loss are the symptoms of PCP. The diagnostic tests include chest X-ray, blood tests, sputum culture, and bronchoscopy. The most common drug used for preventing and treating PCP is co-trimoxazole (trimethoprim and sulfamethoxazole).
The Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) drugs in development market research report provide comprehensive information on the therapeutics under development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
60 Degrees Pharmaceuticals IncCidara Therapeutics Inc
MicroRid Technologies Inc
Opal Biosciences Ltd
Scynexis Inc
University of Pittsburgh
Table of Contents
Table
Figures
Frequently asked questions